Ortho Development expands Trivicta hip stem to full U.S. launch: full analysis
Ortho Development has moved Trivicta from limited release to full U.S. commercialization, marking the company’s latest push in primary hip arthroplasty. In a May 4, 2026, announcement, the Draper, Utah-based manufacturer said the cementless triple-taper femoral stem is now available nationwide through its authorized distribution network after a controlled market introduction. (prnewswire.com)
The launch follows FDA 510(k) clearance first announced by the company on March 14, 2024. At that time, Ortho Development said Trivicta would enter the U.S. market on a limited basis in the second quarter of 2024, with a broader release to follow. That timeline suggests the company spent roughly two years moving from clearance and early-use feedback to full commercial rollout. (newswire.com)
FDA clearance materials add more detail than the launch announcement. The Trivicta stem is a Class II device intended for total and hemi-hip arthroplasty using uncemented press-fit fixation. It is made from titanium alloy, offered in collared and collarless versions, and uses hydroxyapatite plus porous sintered bead coating to support fixation. The clearance summary also notes compatibility with several Ortho Development components, including cobalt-chrome and ceramic femoral heads, as well as the company’s acetabular systems and liners. FDA listed DePuy Synthes’ Actis DuoFix Hip Prosthesis and Ortho Development’s own Entrada Hip Stem among the predicate devices used for substantial equivalence. (accessdata.fda.gov)
In its public product materials, Ortho Development says the triple-taper design is intended to balance fixation, stability, and anatomical control while supporting bone conservation and surgical efficiency. When the company announced clearance in 2024, orthopedic surgeon Dr. Marc Hungerford of Mercy Medical Center said the geometry should allow a precise fit across a range of femoral morphologies and highlighted the system’s ability to provide direct lateralization independent of leg length through extended offset options. Those comments came in company-distributed materials, so they should be read as supportive expert perspective rather than independent post-market evaluation. (odev.com)
The broader market context helps explain why this matters commercially. Cementless fixation remains the prevailing approach in U.S. primary total hip arthroplasty. A 2024 AAOS presentation reported that femoral stem utilization in 2021 was about 80% cementless, while a summary of the 2023 American Joint Replacement Registry annual report said cemented femoral fixation represented just 4.55% of elective primary THA procedures. A recent registry-focused review likewise described a long-term U.S. trend toward uncemented femoral fixation. In other words, Trivicta is entering a segment where surgeon familiarity and demand already favor the underlying fixation strategy. (index.mirasmart.com)
Why it matters: For veterinary professionals, there’s no immediate companion-animal practice implication in this human orthopedic product launch. Still, it’s relevant as a signal of where implant development continues to concentrate: cementless fixation, anatomy-matching stem geometry, modular compatibility, and workflow-friendly instrumentation. Those themes often spill over into veterinary orthopedics through design philosophy, surgeon expectations, and distributor education, even when the specific implant is human-only. It also underscores how device makers are increasingly pairing modest design refinements with staged launches and early market feedback before national rollout. (prnewswire.com)
What to watch: The next meaningful proof points will be external, not promotional: first-use reports outside company channels, any registry participation or peer-reviewed outcomes, and whether Ortho Development publishes comparative data on fit, stability, revision risk, or surgeon preference versus established cementless stems. If those data emerge, they’ll tell the market whether Trivicta is simply another portfolio addition or a product that can win meaningful share in a crowded primary hip segment. (prnewswire.com)